Blog

Court reinstates $236 million verdict against Teva for marketing generic version of Coreg® as “AB rated”

Federal Circuit affirms PTAB decision that concentration of industrial antifungal agent in toenail fungus solution would have been obvious.

505(b)(2) application skirts PTE to introduce metabolite of Biogen’s Tecfidera®.

Generic competition looms for Amarin’s Vascepa (“icosapent ethyl” or “EPA”) capsules in spite of 52 patents listed in FDA’s Orange Book.

Contract requiring disputes to be adjudicated in England did not apply because it was not clear whether English Court would consider claims for U.S. patent infringement.

Federal Circuit rules that Argentum cannot pursue its appeal of a PTAB decision declining to institute an inter-partes review, even though Argentum might be estopped to challenge the patent in subsequent Hatch Waxman litigation

Federal Circuit affirms trial court decision that dose could have been arrived at by routine experimentation.

Federal Circuit affirms PTAB decision that the use of a surfactant to prevent aggregation of insulin glargine would have been obvious.

PTAB provides two step road map for securing companion diagnostic and other biomarker-based patents.

PTAB reverses Examiner’s decision that intrathecal dose would have been arrived at by “routine optimization”